FLUPHENAZINE showed no clear difference in response to treatment compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (moderate certainty).
FLUPHENAZINE showed no clear difference in acceptability of treatment‐leaving the study early due to any reason compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (moderate certainty).
FLUPHENAZINE showed no clear difference in adverse effects‐at least one adverse effect compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (moderate certainty).
FLUPHENAZINE may leads to higher adverse effects‐movement disorders‐at least one movement disorder compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (low certainty).
FLUPHENAZINE leads to lower adverse effects‐other‐sedation compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (high certainty).
HALOPERIDOL showed no clear difference in clinical response to treatment compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (low certainty).
HALOPERIDOL showed no clear difference in leaving the study early ‐ Due to any reason compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (low certainty).
It is very uncertain whether HALOPERIDOL changes adverse effects ‐ at least one adverse effect compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (very low certainty).
HALOPERIDOL may leads to higher adverse effects ‐ movement disorders ‐ At least one movement disorder compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (low certainty).
HALOPERIDOL probably leads to lower adverse effects ‐ other ‐ Sedation compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (moderate certainty).
Comparison 1: PERPHENAZINE showed no clear difference in response to treatment compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (moderate certainty).
It is very uncertain whether comparison 1: PERPHENAZINE changes acceptability of treatment ‐ leaving the study early due to any reason compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (very low certainty).
Comparison 1: PERPHENAZINE showed no clear difference in adverse effects ‐ at least one adverse effect compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (low certainty).
Comparison 1: PERPHENAZINE showed no clear difference in adverse effects ‐ movement disorders ‐ at least one movement disorder compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (low certainty).